Joenja lower doses (leniolisib) for Activated PI3K delta syndrome (APDS), children 4 to 11 weighing 13 to 27 kg
The FDA is expected to decide on Joenja lower doses for Activated PI3K delta syndrome (APDS), children 4 to 11 weighing 13 to 27 kg by January 30, 2027, under a sNDA from Pharming Group.
What is being decided
Pharming Group has a sNDA under FDA review for Joenja lower doses (leniolisib) in Activated PI3K delta syndrome (APDS), children 4 to 11 weighing 13 to 27 kg. Follow-on filing to expand Joenja's September 2026 pediatric approval (ages 4-11, at least 27 kg) down to children weighing as little as 13 kg, using weight-based dosing. Supported by an open-label, multinational, single-arm Phase 3 study showing improvements in lymphadenopathy and naive B cell counts. Priority review.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Frequently asked questions
When will the FDA decide on Joenja lower doses?
The FDA's target decision date (PDUFA date) for Joenja lower doses in Activated PI3K delta syndrome (APDS), children 4 to 11 weighing 13 to 27 kg is January 30, 2027, disclosed by Pharming Group. The agency can act before this date and occasionally runs past it.
What is Joenja lower doses being reviewed for?
Pharming Group submitted a sNDA for Joenja lower doses in Activated PI3K delta syndrome (APDS), children 4 to 11 weighing 13 to 27 kg. Follow-on filing to expand Joenja's September 2026 pediatric approval (ages 4-11, at least 27 kg) down to children weighing as little as 13 kg, using weight-based dosing. Supported by an open-label, multinational, single-arm Phase 3 study showing improvements in lymphadenopathy and naive B cell counts. Priority review.
What happens after the Joenja lower doses decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Pharming press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.